Immunitybio (NASDAQ:IBRX) is a biotechnology firm focused on developing next-generation therapies to strengthen the immune system's ability to fight cancer and infectious diseases. The company is harnessing cutting-edge science to create novel immunotherapies and vaccines that aim to address some of the most challenging medical conditions. Immunitybio's projects span a broad spectrum of clinical trials targeted at various cancers, including bladder, lung, and breast cancer, as well as efforts to combat COVID-19. The primary objective of Immunitybio is to revolutionize treatment paradigms by bringing to market therapies that can potentially provide durable, long-term remission for patients battling with severe diseases.